• Prognostic value of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 Trial
    C. Morvant, C. Bailly, T. Carlier, G. Frecon, F. Kraeber-Bodéré, S. Le Gouill, E. Macintyre, C. Bodet-Milin,
    J. Nucl. Med. Meeting Abstracts, SNM congress 2022, Vancouver, Canada

  • Targeted Alpha-Therapy for the treatment of Acute Myeloid Leukemia
    Sorin M, Gouard S, Marionneau-Lambot S, Eychenne R, Maingueneau C, Ligeour M, Guilloux Y, Allard M, Guérard F, Chérel M, Gaschet J
    15th Workshop New modalities in Cancer Imaging and Therapy, Erquy, France, october 5-8 2022

  • Development and PET/CT preclinical evaluation of anti-CXCR4 antibody in triple-negative breast cancer (TNBC) murine model
    Métivier C, El Ayoubi N, Le Saëc P, Garcion E, Tripier R, Haddad F, Chérel M, Huclier S, Faivre-Chauvet A, Rbah-Vidal L
    15th Workshop New modalities in Cancer Imaging and Therapy, Erquy, France, october 5-8 2022

  • Neutral Copper(II) TE1PA-based chelate for 64Cu-PET imaging : when an additional carboxyl group makes the difference
    Pineau J, Lima LMP, Marionneau-Lambot S, Le Saëc P, Faivre-Chauvet A, Zeevaart JR, Driver CHS, Le Bris N, Tripier R
    15th Workshop New modalities in Cancer Imaging and Therapy, Erquy, France, october 5-8 2022